LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repair. Issue 3 (26th February 2021)

• Record Type: Journal Article
• Authors: Chen, Lifeng; Hou, Jing; Zeng, Xiangyu; Guo, Qiang; Deng, Min; Kloeber, Jake A; Tu, Xinyi; Zhao, Fei; Wu, Zheming; Huang, Jinzhou; Luo, Kuntian; Kim, Wootae; Lou, Zhenkun
• Is Part Of: Clinical and translational medicine. Volume 11:Issue 3(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-02-26
• Subjects: HR -- LRRK2 inhibitor -- PARP inhibitor -- Rad51; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1002/ctm2.341
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: PARP inhibitors induce DNA lesions, the repair of which are highly dependent on homologous recombination (HR), and preferentially kill HR‐ deficient cancers. However, cancer cells have developed several mechanisms to transform HR and confer drug resistance to PARP inhibition. Therefore, there is a great clinical interest in exploring new therapies that induce HR deficiency (HRD), thereby sensitizing cancer cells to PARP inhibitors. Here, we found that GSK2578215A, a high‐selective and effective leucine‐rich repeat kinase 2 (LRRK2) inhibitor, or LRRK2 depletion suppresses HR preventing the recruitment of RAD51 to DNA damage sites through disruption of the interaction of RAD51 and BRCA2. Moreover, LRRK2 inhibition or depletion increases the susceptibility of ovarian cancer cells to Olaparib in vitro and in vivo. In clinical specimens, LRRK2 high expression is high related with advanced clinical characteristics and poor survival of ovarian cancer patients. All these findings indicate ovarian cancers expressing high levels of LRRK2 are more resistant to treatment potentially through promoting HR. Furthermore, combination treatment with an LRRK2 and PARP inhibitor may be a novel strategy to improve the effectiveness of LRRK2 expression ovarian cancers. Abstract : LRRK2 inhibitor GSK2578215A suppresses HR and sensitizes ovarian cancer cells to PARP inhibitor. LRRK2 inhibition impedes the recruitment of RAD51 by disrupting the interaction of RAD51 and BRCA2. High expression of LRRK2 is associated with poor survival of ovarian cancer patients.